Purinergic modulation of the autoimmune vascular phenotype
自身免疫血管表型的嘌呤能调节
基本信息
- 批准号:10168724
- 负责人:
- 金额:$ 15.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-01-01 至 2022-12-30
- 项目状态:已结题
- 来源:
- 关键词:AdenosineAgonistAnti-Inflammatory AgentsAntiphospholipid AntibodiesAtherosclerosisAutoantibodiesAutoimmune DiseasesAutoimmune ProcessAutomobile DrivingBlood PlateletsBlood VesselsBlood coagulationBone MarrowCellsCessation of lifeChromatinClinicalCoagulation ProcessDataDiseaseEndothelial CellsEndotheliumEnzymesEventFibrinolytic AgentsFunctional disorderGenetic ModelsGoalsHumanHydrocarbonsIn SituIn VitroInflammationInterventionKnock-outLaboratoriesLeukocytesLupusMediatingMediator of activation proteinMinorityModelingMusMyocardial InfarctionNeurofibrillary TanglesNeutrophil ActivationNeutrophil InfiltrationOxidative StressPathway interactionsPatientsPhenotypePristanePurine NucleotidesPurinergic P1 ReceptorsPurinoceptorRelaxationRespiratory BurstSignal PathwaySignal TransductionStrokeSurfaceSystemic Lupus ErythematosusTherapeuticThrombosisThrombusTissuesVenousVenous ThrombosisWild Type MouseWomanWorkdifferential expressionendothelial dysfunctionexperienceexperimental studyextracellularinflammatory milieuinsightlupus prone micemouse modelneutrophilnovelnovel strategiespreventreceptorreconstitutiontargeted treatmentthromboinflammationvasoconstriction
项目摘要
ABSTRACT
Dead and dying cells release purine nucleotides, which engage purinergic receptors on the surfaces of
leukocytes, platelets, and vascular cells to trigger inflammation, coagulation, and vasoconstriction. To counter
these mediators of vascular disequilibrium, leukocytes and endothelial cells express surface ectonucleotidases
(CD39 and CD73), which catalyze the step-wise phosphohydrolysis of ATP into adenosine—thereby creating
an anti-inflammatory, antithrombotic “halo” around the cell. In patients with systemic lupus erythematosus
(commonly referred to as “lupus”), stroke and venous thrombosis are relentlessly driven by oxidative stress
and prothrombotic autoantibodies. Furthermore, our laboratory recently discovered that neutrophil extracellular
traps (NETs, tangles of chromatin expelled by “NETosis”) trigger endothelial damage and in situ thrombosis in
lupus. Our preliminary data now reveal that, in lupus, CD73 counteracts neutrophil infiltration, NETosis,
dysfunction of the arterial endothelium, and venous thrombosis. The hypothesis driving this work is that CD73
and its downstream pathways serve as an endogenous (and potentially amplifiable) counterpoint to thrombo-
inflammatory events in lupus.
The Aims of this project are to: (1) Elucidate cell- and receptor-specific mechanisms by which CD73 protects
against lupus-mediated dysfunction of the arterial endothelium. In addition to two traditional models of murine
lupus, we will use a novel approach whereby the administration of human lupus autoantibodies into mice
rapidly triggers endothelial dysfunction. Endpoints will determine the mechanism(s) by which CD73 and
adenosine receptors (A2A, A2B, A3) thwart arterial inflammation and endothelial dysfunction in lupus-prone mice,
and will define the extent to which lineage-specific expression of CD73 (neutrophils vs. endothelium) guards
against these phenotypes. Endpoints will also globally assess the deranged autoimmune/inflammatory milieu
of lupus. (2) Ascertain how CD73 and downstream purinergic signaling modulate lupus-mediated venous
thrombosis. Experiments will again leverage traditional models of murine lupus, as well as a novel model
whereby human lupus autoantibodies markedly potentiate venous thrombosis in mice. We will determine the
extent to which lineage-specific expression of CD73 protects against venous thrombosis, and will elucidate
mechanism(s) by which CD73 and adenosine receptors mitigate autoantibody-mediated NETosis.
Overall, these studies should yield new insight into how a pathway that functions as an endogenous guardian
against inflammation may be exploited to counteract the relentless thrombo-inflammatory course of lupus.
摘要
死亡和垂死的细胞释放嘌呤核苷酸,这些核苷酸与细胞表面的嘌呤能受体结合
白血球、血小板和血管细胞引发炎症、凝血和血管收缩。去反击
这些血管失衡的介质、白细胞和内皮细胞表达表面胞外核苷酸酶。
(CD39和CD73),它催化ATP逐步磷酸水解为腺苷-从而产生
细胞周围有一个抗炎、抗血栓的“光环”。系统性红斑狼疮患者
(通常称为“狼疮”),中风和静脉血栓形成是由氧化应激无情地驱动的。
和血栓前自身抗体。此外,我们实验室最近发现,中性粒细胞胞外
陷阱(网,“网状结构”排出的染色质缠结)引发血管内皮细胞损伤和原位血栓形成。
狼疮。我们的初步数据现在显示,在狼疮中,CD73可以抵消中性粒细胞的渗透,网织,
动脉内皮功能障碍和静脉血栓形成。推动这项工作的假设是CD73
它的下游通路是血栓形成的内源性(而且可能是可放大的)对应物。
狼疮中的炎性事件。
这个项目的目的是:(1)阐明CD73保护细胞和受体的特定机制
抗狼疮所致的动脉内皮功能障碍。除了两种传统的小鼠模型
狼疮,我们将使用一种新的方法,将人类狼疮自身抗体注射到小鼠体内
迅速引发内皮功能障碍。端点将决定CD73和CD73的机制(S)
腺苷受体(A2A、A2B、A3)抑制狼疮易感小鼠动脉炎症和内皮功能障碍
并将确定CD73(中性粒细胞与内皮细胞)的谱系特异性表达在多大程度上保护
来对抗这些表型。终端还将在全球范围内评估错乱的自身免疫/炎症环境
狼疮的症状。(2)确定CD73及其下游的嘌呤能信号如何调节狼疮介导的静脉
血栓形成。实验将再次利用传统的小鼠狼疮模型以及一种新的模型
人类狼疮自身抗体可显著增强小鼠的静脉血栓形成。我们将确定
CD73的谱系特异性表达在多大程度上保护静脉血栓形成,并将阐明
CD73和腺苷受体减轻自身抗体介导的NET中毒的机制(S)。
总体而言,这些研究应该会对作为内源性守护者的一条途径如何发挥作用产生新的见解
抗炎症可能被用来对抗狼疮持续的血栓炎症过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason Knight其他文献
Jason Knight的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason Knight', 18)}}的其他基金
NETs as therapeutic targets in obstetric APS
NETs 作为产科 APS 的治疗靶点
- 批准号:
10786977 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
Purinergic modulation of the autoimmune vascular phenotype
自身免疫血管表型的嘌呤能调节
- 批准号:
10364621 - 财政年份:2018
- 资助金额:
$ 15.6万 - 项目类别:
Purinergic modulation of the autoimmune vascular phenotype
自身免疫血管表型的嘌呤能调节
- 批准号:
10581346 - 财政年份:2018
- 资助金额:
$ 15.6万 - 项目类别:
Innate Immunity in the Pathogenesis of Lupus and Antiphospholipid Vasculopathy
狼疮和抗磷脂血管病发病机制中的先天免疫
- 批准号:
9392606 - 财政年份:2014
- 资助金额:
$ 15.6万 - 项目类别:
Innate Immunity in the Pathogenesis of Lupus and Antiphospholipid Vasculopathy
狼疮和抗磷脂血管病发病机制中的先天免疫
- 批准号:
8751822 - 财政年份:2014
- 资助金额:
$ 15.6万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 15.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 15.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 15.6万 - 项目类别: